EVAL OF ANTI-INFLAMMATORY EFFECTS OF AZITHROMYCIN IN PTS W/CF

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。患有囊性纤维化（CF）的儿童有患与慢性炎症和下呼吸道感染相关的终末期肺病的风险。尽管在过去的20年里，CF患者的长期生存率有了令人鼓舞的趋势，但肺部疾病仍然是CF患者发病和死亡的最常见原因。尽管抗炎治疗通常被认为对患者有益，但目前还没有单一的药物在这类患者群体中广泛使用，主要是由于对口服类固醇和布洛芬等先前研究过的药物的长期安全性的担忧。最近完成的一项关于阿奇霉素在CF患者中使用的研究结果非常有希望，促使囊性纤维化基金会向CF护理人员发布新闻稿，建议考虑在选定的患者中使用阿奇霉素。本临床研究项目旨在描述阿奇霉素在我们佛罗里达大学诊所接受这种治疗的儿童中的抗炎作用。需要验证的假设是，在接受阿奇霉素治疗的患者中，痰炎标志物的下降伴随着临床获益。结果将确定这种治疗的效用，因为它与所声称的作用机制有关。研究结果不仅将提供与患者直接护理相关的临床信息，而且还将补充我们正在进行的关于cf相关肺病儿童肺部疾病发病机制的研究工作。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Children with the cystic fibrosis (CF) are at risk for end stage lung disease associated with chronic inflammation and infection of the lower respiratory tract. Despite encouraging trends in long term survival over the past 20 years, pulmonary disease remains the most common cause of morbidity and mortality in patients with CF. Although anti-inflammatory therapy is generally thought to be of benefit to patients, there is no single agent currently in wide-spread use in this patient population, primarily due to concerns regarding the long-term safety of previously studied agents such as oral steroids and ibuprofen. The results of a recently completed study on the use of azithromycin in patients with CF were promising enough to prompt the Cystic Fibrosis Foundation to issue a news release to CF caregivers recommending consideration of its use in selected patients. This clinical research project is designed to characterize the anti-inflammatory effect of azithromycin in children placed on this treatment in our clinic at the University of Florida. The hypothesis to be tested is that a decline in sputum inflammatory markers accompanies clinical benefit in patients treated with azithromycin. Results will define the utility of this treatment as it relates to the purported mechanism of action. Findings will not only provide clinical information relevant to direct patient care, but will also complement our ongoing research efforts regarding the pathogenesis of lung disease in children with CF-related lung disease.